ArticleImmunity, inflammation and disease2026
A Nomogram Based on the Castelli Risk Index for Predicting Prognosis in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Cohort Study.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
aimsComposite lipid indices are closely related to the risk and poor prognosis of diseases. However, there are no studies on the prognostic value of Castelli's risk indices-I and II (CRI-I, CRI-II) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Therefore, the aim of this study was to investigate the association of CRI-I and CRI-II with the prognosis of patients with ACS undergoing PCI. PATIENTS AND
methodsA total of 1475 patients with ACS undergoing PCI were consecutively enrolled in this prospective cohort study from January 2016 to December 2018. The CRI-I and CRI-II were measured. The endpoints were MACEs, including all-cause mortality, requirement of rehospitalization for severe heart failure, recurrence of myocardial infarction, in-stent restenosis, and reaccept PCI. Follow-up data were collected via clinical visits or telephone calls at 1, 3, 6, and 12 months and annually thereafter.
resultMultivariable Cox regression analysis revealed that the risk of MACEs increased gradually with increasing CRI-I and CRI-II. The cumulative survival rate in the CRI-I ≥ 3.350 and CRI-II ≥ 1.697 groups was significantly lower than that in the CRI-I < 3.350 and CRI-II < 1.697 groups, respectively (log-rank tests: all p < 0.001). The nomogram demonstrated good predictive performance for the 1-, 2-, and 3-year survival probability.
conclusionsCRI-I ≥ 3.350 and CRI-II ≥ 1.697 could serve as independent predictors of MACEs in patients with ACS undergoing PCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.